Autolus Therapeutics (AUTL)
NASDAQ: AUTL
· Real-Time Price · USD
1.73
-0.12 (-6.49%)
At close: Aug 15, 2025, 3:46 PM
-6.49% (1D)
| Bid | 1.34 |
| Market Cap | 459.07M |
| Revenue (ttm) | 9.01M |
| Net Income (ttm) | -238.13M |
| EPS (ttm) | -0.87 |
| PE Ratio (ttm) | -1.98 |
| Forward PE | -3.24 |
| Analyst | Buy |
| Ask | 2.2 |
| Volume | 11,054,548 |
| Avg. Volume (20D) | 2,255,751.4 |
| Open | 1.85 |
| Previous Close | 1.85 |
| Day's Range | 1.65 - 1.88 |
| 52-Week Range | 1.10 - 5.00 |
| Beta | 1.90 |
About AUTL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AUTL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AUTL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Autolus Therapeutics is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 days ago
-12.96%
Autolus Therapeutics shares are trading lower. The...
Unlock content with
Pro Subscription
3 weeks ago
+0.83%
Autolus Therapeutics shares are trading higher after the company announced that AUCATYZL has been granted a European marketing authorization.
2 months ago · seekingalpha.com
Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune MarketAutolus Therapeutics plc is a UK-based biotech that has brought its ex-vivo CAR-T cell therapy to market in B-ALL with a "best-in-class" safety/efficacy profile. In this small indication, peak revenue...
